None listed
Conditions
Brief summary
The incidence of neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD) disease are expected to rise in the next 30 years as a result of Australia’s ageing population. However, conclusive diagnostic tests and impact of dietary status for neurodegenerative disease risk are not clearly defined. Therefore, it is important to identify potential genome damage biomarkers and micronutrients associated with these diseases that may aid in the design of potential preventative measures. The hypothesis is mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease exhibit increases in genome damage and cell death biomarkers relative to each other, and to healthy age matched controls.
Interventions
Using cytokinesis block micronucleus cytome assay to identify cell genome damage biomarkers for mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. This study will take place for 2 years.
Sponsors
Commonwealth Scientific and Industrial Research Organisation
Eligibility
Sex/Gender
All
Age
55 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
Control Group: Male or female, Aged 55 and above, Not clinically diagnosed with mild cognitive impairment, Alzheimer's disease and Parkinson's, No family history of mild cognitive impairment, Alzheimer's disease and Parkinson's disease Mild cognitive impairment Group: Male or female, Aged 55 and above, Clinically diagnosed with mild cognitive impairment Alzheimer's disease Group: Male or female, Aged 55 and above, Clinically diagnosed with Alzheimer's disease Parkinson's disease Group: Male or female, Aged 55 or above, Clinically diagnosed with Parkinson's disease
Exclusion criteria
Control Group: Patients who are undergoing chemotherapy,radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance Mild cognitive impairment Group: Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance Alzheimer's disease Group: Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance Parkinson's disease Group: Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance
Outcome results
None listed